FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications (2011)

Government Record · U.S. Food and Drug Administration (FDA) · October 20, 2011

U.S. Food, 2011-10-20: The October 2011 follow-up update to the July 2011 communication narrows the case series to IV methylene blue used as a surgical visualising agent (1-8 mg/kg) and says risk by other routes or below 1 mg/kg is unknown.

Most cases from the FDA's Adverse Event Reporting System (AERS) of serotonin syndrome in patients given serotonergic psychiatric medications and methylene blue occurred in the context of parathyroid surgery, which involved the intravenous administration of methylene blue as a visualizing agent.

U.S. Food, 2011-10-20: The October 2011 follow-up update to the July 2011 communication narrows the case series to IV methylene blue used as a surgical visualising agent (1-8 mg/kg) and says risk by other routes or below 1 mg/kg is unknown. Study type: regulatory record.